Research affiliate, George Mason University
Bestätigte E-Mail-Adresse bei
Zitiert von
Zitiert von
The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
J Hallin, LD Engstrom, L Hargis, A Calinisan, R Aranda, DM Briere, ...
Cancer discovery 10 (1), 54-71, 2020
Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors …
V Ludovini, F Bianconi, L Pistola, R Chiari, V Minotti, R Colella, D Giuffrida, ...
Journal of thoracic oncology 6 (4), 707-715, 2011
Multiclass HCV resistance to direct‐acting antiviral failure in real‐life patients advocates for tailored second‐line therapies
VC Di Maio, V Cento, I Lenci, M Aragri, P Rossi, S Barbaliscia, M Melis, ...
Liver international 37 (4), 514-528, 2017
Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell …
V Ludovini, I Floriani, L Pistola, V Minotti, M Meacci, R Chiari, ...
Journal of thoracic oncology 6 (12), 2018-2026, 2011
Computational model of EGFR and IGF1R pathways in lung cancer: a systems biology approach for translational oncology
F Bianconi, E Baldelli, V Ludovini, L Crinò, A Flacco, P Valigi
Biotechnology advances 30 (1), 142-153, 2012
Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations
V Ludovini, F Bianconi, L Pistola, V Minotti, R Chiari, R Colella, ...
Cancer chemotherapy and pharmacology 69, 1289-1299, 2012
Reverse phase protein microarrays
E Baldelli, V Calvert, A Hodge, A VanMeter, EF Petricoin, M Pierobon
Molecular profiling: methods and protocols, 149-169, 2017
The sustained induction of c-MYC drives nab-paclitaxel resistance in primary pancreatic ductal carcinoma cells
E Parasido, GS Avetian, A Naeem, G Graham, M Pishvaian, E Glasgow, ...
Molecular Cancer Research 17 (9), 1815-1827, 2019
Impact of upfront cellular enrichment by laser capture microdissection on protein and phosphoprotein drug target signaling activation measurements in human lung cancer …
E Baldelli, EB Haura, L Crinò, DW Cress, V Ludovini, MB Schabath, ...
PROTEOMICS–Clinical Applications 9 (9-10), 928-937, 2015
Functional characterization of epithelial ovarian cancer histotypes by drug target based protein signaling activation mapping: implications for personalized cancer therapy
MI Sereni, E Baldelli, G Gambara, J Deng, L Zanotti, E Bandiera, ...
Proteomics 15 (2-3), 365-373, 2015
Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors
E Baldelli, G Bellezza, EB Haura, L Crinó, WD Cress, J Deng, V Ludovini, ...
Oncotarget 6 (32), 32368, 2015
Concomitant high gene copy number and protein overexpression of IGF1R and EGFR negatively affect disease-free survival of surgically resected non-small-cell-lung cancer patients
V Ludovini, A Flacco, F Bianconi, M Ragusa, J Vannucci, G Bellezza, ...
Cancer chemotherapy and pharmacology 71 (3), 671-680, 2013
A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser capture microdissection and reverse phase protein microarray
E Pin, S Stratton, C Belluco, L Liotta, R Nagle, KA Hodge, J Deng, T Dong, ...
Molecular Oncology 10 (10), 1585-1594, 2016
Integrated multi-omics analyses on patient-derived CRC organoids highlight altered molecular pathways in colorectal cancer progression involving PTEN
M Codrich, E Dalla, C Mio, G Antoniali, MC Malfatti, S Marzinotto, ...
Journal of Experimental & Clinical Cancer Research 40 (1), 1-17, 2021
Conditional robustness analysis for fragility discovery and target identification in biochemical networks and in cancer systems biology
F Bianconi, E Baldelli, V Luovini, EF Petricoin, L Crinò, P Valigi
BMC systems biology 9, 1-18, 2015
The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer
JN Diehl, JE Klomp, KR Snare, PS Hibshman, DR Blake, ZD Kaiser, ...
Journal of Biological Chemistry 297 (5), 2021
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer
CM Goodwin, AM Waters, JE Klomp, S Javaid, KL Bryant, CA Stalnecker, ...
Cancer Research 83 (1), 141-157, 2023
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels
VC Di Maio, V Cento, D Di Paolo, M Aragri, F De Leonardis, ...
Journal of Antimicrobial Chemotherapy 71 (3), 739-750, 2016
CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment
JE Klomp, YS Lee, CM Goodwin, B Papke, JA Klomp, AM Waters, ...
Cell reports 37 (9), 2021
Kinase-driven metabolic signalling as a predictor of response to carboplatin–paclitaxel adjuvant treatment in advanced ovarian cancers
MI Sereni, E Baldelli, G Gambara, A Ravaggi, KA Hodge, DS Alberts, ...
British Journal of Cancer 117 (4), 494-502, 2017
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20